Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis sees positive results

Sanofi-Aventis sees positive results

30th April 2008

Sanofi-Aventis has confirmed that test results from the phase-III study of eplivanserin in the treatment of insomnia have been successful.

The study found that patients who suffered from disturbed sleep spent less time awake after the first onset of sleep when they took the drug compared to those that were given a placebo.

Indeed the number of night-time awakenings reported by users of the drug fell during the study, while people also felt that the quality of sleep improved.

Results of this test also show the new product has a good tolerance profile in relation to the placebo product, with no withdrawal symptoms, rebound phenomenon or any residual effect on waking.

Another product made by Sanofi-Aventis, volinanserin, also reduced the number of night-time awakenings after three and six weeks of treatment, the firm claims.

Earlier this month, Sanofi-Aventis said it has formed strong partnerships with a number of organisations in Africa as part of a move to offer treatments for malaria.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.